Gocatamig

Multispecific antibody

Also known as MK-6070

Phase 3Mechanism not established
Phase 3planned

Evidence outlook · registrational

Small Cell Lung Cancer: registrational trial registered, not yet recruiting

No completed mid-stage readout is on record. Registrational readout expected around 2031-12-08.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Small Cell Lung Cancer
NCT07908537 · Merck Sharp & Dohme LLC
2026-12-07 – 2036-03-10 · Small Cell Lung Cancer
What this study did
Phase 1/2 (3)
Small Cell Lung Cancer
NCT07227597 · Merck Sharp & Dohme LLC
2026-01-29 – 2030-12-30 · Small Cell Lung Cancer Extensive Stage
What this study did
NCT04471727 · Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
2020-12-14 – 2028-01-28 · Small-Cell Lung Cancer, Neuroendocrine Carcinoma
What this study did

Competitive landscape

This drug's own stage for Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Gocatamig: this drugPhase 3Multispecific antibody—not yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
LurbinectedinApprovedSmall moleculeAlkylating DrugPartial signalNo reviewed efficacy summary in this indication
TarlatamabApprovedMultispecific antibodyDLL3 and CD3Partial signal
NCT06211036: Primary endpoint, overall survival: met at a pre-specified interim analysis (Amgen, 2026-09-08).
NCT05740566: Overall survival: median 13.6 months (95% CI 11.1 to not reached) vs 8.3 months (95% CI 7.0 to 10.2) on chemotherapy; stratified hazard ratio for death 0.60 (DeLLphi-304, NEJM 2025).
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
ABBV-706Phase 3Antibody–drug conjugateSEZ6not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
AL8326Phase 3Small moleculeAurora B / FGFR / VEGFR (multi-kinase)Weak signal
NCT04890795: ORR 20% (6/30, 4 confirmed responses); median PFS 3.65 months; median OS 10.42 months in 30 evaluable ≥3rd-line SCLC patients (data cutoff Nov 30, 2022)
AtigotatugPhase 3Monoclonal antibody—not yet gradedNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
ObrixtamigPhase 3Multispecific antibodyDLL3 (Delta-like ligand 3) x CD3not yet gradedNo reviewed efficacy summary in this indication
PumitamigPhase 3Multispecific antibodyPD-L1 and VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
SerplulimabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
TislelizumabPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AlisertibPhase 2Small moleculeAurora kinase A (AURKA)not yet gradedNo reviewed efficacy summary in this indication
BMS-986525Phase 1/2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
DJI136Phase 1/2Cell therapyDLL3not yet gradedNo reviewed efficacy summary in this indication
Quaratusugene Ozeplasmid (Reqorsa)Phase 1/2Gene therapy / editingTUSC2 (tumor suppressor gene replacement)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Gocatamig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
January 2028 (1)
Phase 1/2Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-28 · NCT04471727 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2029-02-15 · NCT06780137 · CT.gov ↗
What to watch
2030 (1)
November 2030 (1)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2030-11-29 · NCT07227597 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 3Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-12-08 · NCT07908537 · CT.gov ↗
What to watch

See the full readout calendar ↗